PortalPublikationenPrevention and treatment of relapse after stem cell transpla...

Prevention and treatment of relapse after stem cell transplantation in lymphoid malignancies

Standard

Prevention and treatment of relapse after stem cell transplantation in lymphoid malignancies. / Sureda, Anna; Dreger, Peter; Bishop, Michael R; Kroger, Nicolaus; Porter, David L.

in: BONE MARROW TRANSPL, Jahrgang 54, Nr. 1, 01.2019, S. 17-25.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung

Harvard

Sureda, A, Dreger, P, Bishop, MR, Kroger, N & Porter, DL 2019, 'Prevention and treatment of relapse after stem cell transplantation in lymphoid malignancies', BONE MARROW TRANSPL, Jg. 54, Nr. 1, S. 17-25. https://doi.org/10.1038/s41409-018-0214-5

APA

Sureda, A., Dreger, P., Bishop, M. R., Kroger, N., & Porter, D. L. (2019). Prevention and treatment of relapse after stem cell transplantation in lymphoid malignancies. BONE MARROW TRANSPL, 54(1), 17-25. https://doi.org/10.1038/s41409-018-0214-5

Vancouver

Sureda A, Dreger P, Bishop MR, Kroger N, Porter DL. Prevention and treatment of relapse after stem cell transplantation in lymphoid malignancies. BONE MARROW TRANSPL. 2019 Jan;54(1):17-25. https://doi.org/10.1038/s41409-018-0214-5

Bibtex

@article{8532d7dc3c4c4a2889d612d08535ea4f,
title = "Prevention and treatment of relapse after stem cell transplantation in lymphoid malignancies",
abstract = "Relapse is now the major cause of treatment failure after allogeneic HSCT (alloHSCT). Many novel strategies to address this critical issue are now being developed and tested. At the 3rd International Workshop on Biology, Prevention, and Treatment of Relapse held in Hamburg, Germany in November 2016, international experts presented and discussed recent developments in the field. Some approaches may be applicable to a wide range of patients after transplant, whereas some may be very disease-specific. We present a report from the session dedicated to issues related to prevention and treatment of relapse of lymphoid malignancies after alloHSCT. This session included detailed reviews as well as forward-looking commentaries that focused on Hodgkin lymphoma, chronic lymphocytic leukemia and mantle cell lymphoma, diffuse large cell and follicular lymphoma, and multiple myeloma.",
keywords = "Congresses as Topic, Germany, Hematologic Neoplasms/prevention & control, Hematopoietic Stem Cell Transplantation, Hodgkin Disease/prevention & control, Humans, Lymphoma, Non-Hodgkin/prevention & control, Multiple Myeloma/prevention & control, Recurrence, Transplantation, Homologous",
author = "Anna Sureda and Peter Dreger and Bishop, {Michael R} and Nicolaus Kroger and Porter, {David L}",
year = "2019",
month = jan,
doi = "10.1038/s41409-018-0214-5",
language = "English",
volume = "54",
pages = "17--25",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "1",

}

RIS

TY - JOUR

T1 - Prevention and treatment of relapse after stem cell transplantation in lymphoid malignancies

AU - Sureda, Anna

AU - Dreger, Peter

AU - Bishop, Michael R

AU - Kroger, Nicolaus

AU - Porter, David L

PY - 2019/1

Y1 - 2019/1

N2 - Relapse is now the major cause of treatment failure after allogeneic HSCT (alloHSCT). Many novel strategies to address this critical issue are now being developed and tested. At the 3rd International Workshop on Biology, Prevention, and Treatment of Relapse held in Hamburg, Germany in November 2016, international experts presented and discussed recent developments in the field. Some approaches may be applicable to a wide range of patients after transplant, whereas some may be very disease-specific. We present a report from the session dedicated to issues related to prevention and treatment of relapse of lymphoid malignancies after alloHSCT. This session included detailed reviews as well as forward-looking commentaries that focused on Hodgkin lymphoma, chronic lymphocytic leukemia and mantle cell lymphoma, diffuse large cell and follicular lymphoma, and multiple myeloma.

AB - Relapse is now the major cause of treatment failure after allogeneic HSCT (alloHSCT). Many novel strategies to address this critical issue are now being developed and tested. At the 3rd International Workshop on Biology, Prevention, and Treatment of Relapse held in Hamburg, Germany in November 2016, international experts presented and discussed recent developments in the field. Some approaches may be applicable to a wide range of patients after transplant, whereas some may be very disease-specific. We present a report from the session dedicated to issues related to prevention and treatment of relapse of lymphoid malignancies after alloHSCT. This session included detailed reviews as well as forward-looking commentaries that focused on Hodgkin lymphoma, chronic lymphocytic leukemia and mantle cell lymphoma, diffuse large cell and follicular lymphoma, and multiple myeloma.

KW - Congresses as Topic

KW - Germany

KW - Hematologic Neoplasms/prevention & control

KW - Hematopoietic Stem Cell Transplantation

KW - Hodgkin Disease/prevention & control

KW - Humans

KW - Lymphoma, Non-Hodgkin/prevention & control

KW - Multiple Myeloma/prevention & control

KW - Recurrence

KW - Transplantation, Homologous

U2 - 10.1038/s41409-018-0214-5

DO - 10.1038/s41409-018-0214-5

M3 - SCORING: Review article

C2 - 29795433

VL - 54

SP - 17

EP - 25

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 1

ER -